Heterobivalent ligands target cell-surface receptor combinations in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 52, 2012, Pages 21295-21300

  Xu, Liping ^a   Josan, Jatinder S ^b   Vagner, Josef ^b   Caplan, Michael R ^c   Hruby, Victor J ^b   Mash, Eugene A ^b   Lynch, Ronald M ^d   Morse, David L ^a   Gillies, Robert J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c Arizona State University   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cross linking; Gene expression profiling; Multivalency; Receptor targeting

Indexed keywords

CELL SURFACE RECEPTOR; CHOLECYSTOKININ RECEPTOR; EUROPIUM; FLUORESCENT DYE; MELANOCORTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; CARBOCYANINES; CELL SURVIVAL; EUROPIUM; FLUORESCENCE; HCT116 CELLS; HUMANS; IMAGING, THREE-DIMENSIONAL; KINETICS; LIGANDS; MICE; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; RECEPTORS, CELL SURFACE; STAINING AND LABELING;

ANIMALIA; MUS;

EID: 84871847797     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211762109     Document Type: Article

References (40)

1. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8(6):473-480. (Pubitemid 351752547)
2. Winau F, Westphal O, Winau R (2004) Paul Ehrlich - in search of the magic bullet. Microbes Infect 6(8):786-789. (Pubitemid 38781191)
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400. (Pubitemid 38618122)
4. Ginj M, et al. (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11(3):1136-1145. (Pubitemid 40175763)
5. Shadidi M, Sioud M (2003) Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 6(6):363-371. (Pubitemid 38173587)
6. Kiessling LL, Gestwicki JE, Strong LE (2000) Synthetic multivalent ligands in the exploration of cell-surface interactions. Curr Opin Chem Biol 4(6):696-703.
7. Mammen M, Choi S, Whitesides G (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37(20):2754-2794. (Pubitemid 29008561)
8. Rao J, Lahiri J, Isaacs L, Weis RM, Whitesides GM (1998) A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin. Science 280(5364):708-711. (Pubitemid 28243338)
9. Hong S, et al. (2007) The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 14(1):107-115. (Pubitemid 46124068)
10. Thomas TP, et al. (2005) Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 48(11):3729-3735. (Pubitemid 40776848)
11. Gillies RJ, Hruby VJ (2003) Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets 7(2):137-139. (Pubitemid 36512015)
12. Vagner J, et al. (2008) Heterobivalent ligands crosslink multiple cell-surface receptors: The human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl 47(9):1685-1688.
13. Bostrom J, et al. (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323(5921):1610-1614.
14. Thakur A, Lum LG (2010) Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 12(3):340-349.
15. Caplan MR, Rosca EV (2005) Targeting drugs to combinations of receptors: A modeling analysis of potential specificity. Ann Biomed Eng 33(8):1113-1124. (Pubitemid 41165014)
16. Handl HL, et al. (2004) Hitting multiple targets with multimeric ligands. Expert Opin Ther Targets 8(6):565-586. (Pubitemid 40028367)
17. Josan JS, et al. (2011) Cell-specific targeting by heterobivalent ligands. Bioconjug Chem 22(7):1270-1278.
18. Balagurunathan Y, et al. (2008) Gene expression profiling-based identification of cellsurface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther 7(9):3071-3080.
19. Xu L, et al. (2009) Enhanced targeting with heterobivalent ligands. Mol Cancer Ther 8(8):2356-2365.
20. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343(5):1409-1438. (Pubitemid 39387834)
21. Palczewski K, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289(5480):739-745. (Pubitemid 30650186)
22. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252(11):3582-3586. (Pubitemid 8116088)
23. Bentley MD, Bossard MJ, Burton KW, Viegas TX (2008) Poly(ethylene)glycol conjugates of biopharmaceuticals in drug deliver. Modern Biopharmaceuticals: Design, Development and Optimization, ed Knablein J (Wiley, Weinheim, Germany), pp 1393-1418.
24. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42(5):419-436. (Pubitemid 36649037)
25. Smith J (2012) Cellular processing and stability of a CCK/MSH bivalent ligand. Master's thesis (University of Arizona, Tucson).
26. Josan JS, et al. (2009) Solid-phase synthetic strategy and bioevaluation of a labeled deltaopioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org Lett 11(12):2479-2482.
27. Inglese J, et al. (1998) Chemokine receptor-ligand interactions measured using timeresolved fluorescence. Biochemistry 37(8):2372-2377. (Pubitemid 28119311)
28. Selvin PR (2002) Principles and biophysical applications of lanthanide-based probes. Annu Rev Biophys Biomol Struct 31:275-302.
29. Appel E, Rabinkov A, Neeman M, Kohen F, Mirelman D (2011) Conjugates of daidzeinalliinase as a targeted pro-drug enzyme system against ovarian carcinoma. J Drug Target 19(5):326-335.
30. Mignet N, et al. (2006) Liposome biodistribution by time resolved fluorimetry of lipophilic europium complexes. Eur Biophys J 35(2):155-161. (Pubitemid 43042774)
31. Shewmake TA, Solis FJ, Gillies RJ, Caplan MR (2008) Effects of linker length and flexibility on multivalent targeting. Biomacromolecules 9(11):3057-3064.
32. David A, Kopecková P, Minko T, Rubinstein A, Kopecek J (2004) Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. Eur J Cancer 40(1):148-157. (Pubitemid 37542327)
33. Vagner J, Handl HL, Gillies RJ, Hruby VJ (2004) Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: Homooligomers of alpha- MSH. Bioorg Med Chem Lett 14(1):211-215. (Pubitemid 38010222)
34. Siegrist W, et al. (1989) Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49(22):6352-6358. (Pubitemid 20000936)
35. Brabez N, et al. (2011) Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: Tools toward melanoma diagnosis and treatment. J Med Chem 54(20):7375-7384.
36. DePalatis LR, Frazier KA, Cheng RC, Kotite NJ (1995) Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10- tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res 55(22):5288-5295.
37. Haubner R, et al. (2001) Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42(2):326-336. (Pubitemid 32150525)
38. Mohamadi F, et al. (1990) Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 11(4):440-467.
39. Jonathan M, Goodman W, Still C (1991) An unbounded systematic search of conformational space. J Comput Chem 12(9):1110-1117.
40. Guarnieri F, Still WC (1994) A rapid convergent simulation method: Mixed monte carlo/stochastic dynamics. J Comput Chem 15(11):1302-1310.